Evaluation of ORF-1658, a new formulation for sequential oral contraceptive therapy.
D001835:Body Weight; D002986:Clinical Trials as Topic; D003276:Contraceptives, Oral / Q000009:adverse effects / Q000627:therapeutic use*; D004357:Drug Synergism; D004412:Dysmenorrhea / Q000139:chemically induced; D005260:Female; D006801:Humans; D008598:Menstruation; D008656:Mestranol / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced; D011293:Premenstrual Syndrome / Q000139:chemically induced; D011372:Progestins / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D003276:Contraceptives, Oral; D011372:Progestins; D008656:Mestranol